| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1225 | 2019 |
| IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study G Marcucci, K Maharry, YZ Wu, MD Radmacher, K Mrózek, D Margeson, ... Journal of clinical oncology 28 (14), 2348, 2010 | 951 | 2010 |
| A computerized reminder system to increase the use of preventive care for hospitalized patients PR Dexter, S Perkins, JM Overhage, K Maharry, RB Kohler, CJ McDonald New England Journal of Medicine 345 (13), 965-970, 2001 | 685 | 2001 |
| MicroRNA expression in cytogenetically normal acute myeloid leukemia G Marcucci, MD Radmacher, K Maharry, K Mrózek, AS Ruppert, ... New England Journal of Medicine 358 (18), 1919-1928, 2008 | 538 | 2008 |
| Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia K Mrózek, G Marcucci, D Nicolet, KS Maharry, H Becker, SP Whitman, ... Journal of clinical oncology 30 (36), 4515, 2012 | 525 | 2012 |
| Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics GB Koo, MJ Morgan, DG Lee, WJ Kim, JH Yoon, JS Koo, SI Kim, SJ Kim, ... Cell research 25 (6), 707-725, 2015 | 456 | 2015 |
| An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia KH Metzeler, M Hummel, CD Bloomfield, K Spiekermann, J Braess, ... Blood, The Journal of the American Society of Hematology 112 (10), 4193-4201, 2008 | 449 | 2008 |
| Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t (8; 21) differ from those of patients with inv (16): a Cancer and Leukemia Group B … G Marcucci, K Mrózek, AS Ruppert, K Maharry, JE Kolitz, JO Moore, ... Journal of clinical oncology 23 (24), 5705-5717, 2005 | 445 | 2005 |
| TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study KH Metzeler, K Maharry, MD Radmacher, K Mrózek, D Margeson, ... Journal of clinical oncology 29 (10), 1373, 2011 | 427 | 2011 |
| Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression … H Becker, G Marcucci, K Maharry, MD Radmacher, K Mrózek, ... Journal of clinical oncology 28 (4), 596, 2010 | 426 | 2010 |
| Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk … G Marcucci, K Maharry, MD Radmacher, K Mrózek, T Vukosavljevic, ... Journal of clinical oncology 26 (31), 5078, 2008 | 377 | 2008 |
| ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category KH Metzeler, H Becker, K Maharry, MD Radmacher, J Kohlschmidt, ... Blood, The Journal of the American Society of Hematology 118 (26), 6920-6929, 2011 | 347 | 2011 |
| Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia G Marcucci, KH Metzeler, S Schwind, H Becker, K Maharry, K Mrózek, ... Journal of clinical oncology 30 (7), 742, 2012 | 344 | 2012 |
| RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression … JH Mendler, K Maharry, MD Radmacher, K Mrózek, H Becker, ... Journal of clinical oncology 30 (25), 3109, 2012 | 335 | 2012 |
| Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study P Paschka, G Marcucci, AS Ruppert, SP Whitman, K Mrózek, K Maharry, ... Journal of Clinical Oncology 26 (28), 4595, 2008 | 335 | 2008 |
| Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from … J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ... Journal of Clinical Oncology 39 (4), 273, 2021 | 327 | 2021 |
| Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia S Liu, LC Wu, J Pang, R Santhanam, S Schwind, YZ Wu, CJ Hickey, J Yu, ... Cancer cell 17 (4), 333-347, 2010 | 288 | 2010 |
| Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates: a randomized trial PR Dexter, SM Perkins, KS Maharry, K Jones, CJ McDonald Jama 292 (19), 2366-2371, 2004 | 279 | 2004 |
| FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with … SP Whitman, K Maharry, MD Radmacher, H Becker, K Mrózek, ... Blood, The Journal of the American Society of Hematology 116 (18), 3622-3626, 2010 | 267 | 2010 |
| High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal … G Marcucci, K Maharry, SP Whitman, T Vukosavljevic, P Paschka, ... Journal of clinical oncology 25 (22), 3337-3343, 2007 | 244 | 2007 |
